Stocks Are Getting Closer to a Major Break-out (AVY, FBHS, PNK, REGN)

Los Angelas, CA -- (SBWIRE) -- 10/25/2012 -- Avery Dennison Co (NYSE:AVY) is +2.50 - +8.40% from the previous close of $29.75. It traded between $31.52 - 33.8712 with total traded volume of 2020482 shares. At Current Market Price, AVY is in distance of +4.71% from its 50-day Moving Average price of $30.8006 and +7.47% from its 200-day Moving Average price of $30.0085. Avery Dennison Corporation ( AVY ) reported adjusted earnings of 53 cents per share in the third-quarter 2012, a 77% rise from the 30 cents per share delivered in the year-ago quarter; beating the Zacks Consensus Estimate of 45 cents. Including restructuring costs and other items, earnings from continuing operations were 37 cents per share in the quarter compared with 33 cents in the year-ago quarter. Total revenues dipped 0.8% to $1.488 billion from $1.500 billion in the prior-year quarter. Revenues were ahead of the Zacks Consensus Estimate of $1.487 billion. Cost of sales for the reported quarter fell 3.3% to $1.096 billion. Gross profit increased 7.1% to $392 million from $366.9 million in the prior-year quarter.

What's The Price Target Of AVY: FIND OUT HERE

Shares of Fortune Brands Home & Security (NYSE:FBHS) jumped 10% today after releasing third-quarter earnings. Revenue rose 7% in the quarter to $909.1 million, which was $10.3 million ahead of estimates. On the bottom line, net income jumped from $2.2 million a year ago to $40 million, or $0.24 per share. On an adjusted basis, earnings were $0.29 per share, ahead of estimates of $0.25 from analysts. The improved housing market boosted sales: Kitchen and bath cabinetry rose 6% in the quarter, and plumbing and accessories increased 12%. Management had so much confidence in the results that it increased its full-year EPS outlook to a range of $0.86 to $0.88, above the consensus estimate of $0.83. The stronger earnings are great, but the stock is still too expensive for my taste, so I'll sit this jump out today. Fortune Brands Ho (NYSE:FBHS) is +2.23 - +8.27% from the previous close of $26.97. It traded between $28.23 - 30.27 with total traded volume of 4678721 shares. At Current Market Price, FBHS is in distance of +6.27% from its 50-day Moving Average price of $27.4769 and +23.17% from its 200-day Moving Average price of $23.7067.

Should Investor Exit From FBHS: CHECK HERE

Pinnacle Entertainment, Inc. (NYSE:PNK) is an owner, operator and developer of casinos and related hospitality and entertainment facilities. The Company operates casinos located in Lake Charles, New Orleans and Bossier City, Louisiana , St. Louis, Missouri (River City Casino and Lumiere Place Casino and Hotels), and southeastern Indiana (Belterra Casino Resort). In addition, it owns and operates a racetrack facility in Cincinnati, Ohio.reported that its third-quarter net loss was $358 thousand or $0.01 per share, compared to a loss $790 thousand or $0.01 per share in the same quarter last year.A poll pulled by Thomson Reuters expected the company to report earnings of $0.18 per share for the quarter. Pinnacle is trading at an intraday of $12.67 (+7.65%) with over 380,000 shares exchanged. Pinnacle Entertai (NYSE:PNK) are trading at $12.74 and is +6.89% from its 50-day Moving Average price of $11.9189 and +19.02% from its 200-day Moving Average price of $10.7041. The average trading volume is 591466 shares and its market capitalization is $793.0M.

Get Free Trend Analysis Report On PNK: FIND HERE

Regeneron Pharmac (NasdaqNM:REGN) are trading at $162.69 and is +6.57% from its 50-day Moving Average price of $152.658 and +20.82% from its 200-day Moving Average price of $134.659. The average trading volume is 750172 shares and its market capitalization is $15.389B. Regeneron Pharmaceuticals Inc. on Wednesday reported third-quarter results that far exceeded Wall Street expectations as it won key new approvals for its eye drug Eylea and cancer drug Zaltrap. The company said U.S. sales of Eylea, which was approved in November, rose to $244 million. During the quarter Regeneron received approval to market Eylea in Japan, the world's second-largest pharmaceutical market while U.S. regulators broadened its approval. Regulators also cleared its drug Zaltrap as a secondary treatment for colorectal cancer. The new approvals triggered payments to Regeneron from its partners. The company also raised its full-year sales estimates for Eylea.

Should Investor Hold Or Sell REGN This Range: CLICK HERE To Know More

Disclaimer
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com